Etidronate disodium in postmenopausal osteoporosis

Area of Science:

• Biochemistry
• Pharmacology
• Bone Metabolism

Background:

• Osteoporosis is a significant health concern characterized by low bone mass and increased fracture risk.
• Understanding the effects of therapeutic agents on calcium balance and bone turnover is crucial for managing osteoporosis.

Purpose of the Study:

• To evaluate the effects of disodium etidronate (EHDP) on calcium balance, calcium kinetics, and physiological parameters in osteoporotic patients.
• To assess the safety and efficacy of long-term EHDP treatment in this patient population.

Main Methods:

• 10 osteoporotic patients received oral disodium etidronate (EHDP) at 20 mg/kg/day for 6 to 12 months.
• Calcium balance, calcium kinetics, and various physiological and biochemical markers were monitored throughout the study.
• Absorption, retention, and urinary excretion of EHDP were measured.

Main Results:

• EHDP absorption averaged 10%, with an effective retained dose of approximately 1.6 mg/kg/day.
• EHDP significantly reduced bone resorption and mineralization by approximately 50%.
• Serum phosphorus and calcium levels showed modest elevations; urine calcium and gastrointestinal calcium absorption increased significantly, leading to a positive calcium balance.

Conclusions:

• Disodium etidronate (EHDP) effectively reduces bone resorption and mineralization in osteoporotic patients.
• EHDP treatment resulted in a positive calcium balance with excellent patient tolerance and no significant adverse effects.
• The observed changes in calcium metabolism correlated with urinary EHDP levels, suggesting dose-dependent effects.